Paul Nathan, MBBS, PhD, FRCP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01–positive uveal melanoma.
Paul Nathan, MBBS, PhD, MCRP
Advertisement
Articles by Paul Nathan, MBBS, PhD, MCRP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Study Redefines Functional High-Risk Multiple Myeloma in Modern-Therapy Era
2
ctDNA MRD Guidance in Bladder Cancer: Pharmacy Specialist on NCCN Updates
3
Sequencing Treatment after EV-Pembro in Urothelial Carcinoma
4
Managing Safety and Infection Risk With Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
5